ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck and Sino Biopharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MerckSino Biopharmaceutical
studies on the registry2,455471
open to participants now146163
phase 3 studies under way11246
reach primary completion within a year6057
programswith a study of their own in two years8497+19 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerckSino Biopharmaceutical
Phase 1

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%

Sino Biopharmaceutical: 37 of its 97 programs at phase 1

  1. TQF3250phase 1
  2. TQB2101phase 1
  3. 1200mg of tqb2928 injectionphase 1
  4. Anecatibin Fumarate Capsulesphase 1
  5. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1

and 32 more — sign in to see them all

38%
Phase 223%

Sino Biopharmaceutical: 31 of its 97 programs at phase 2

  1. JAK2 Inhibitor TQ05105phase 2
  2. TQB2922phase 2
  3. TRD205phase 2
  4. BTK Inhibitor TQB3702phase 2
  5. TQB6411phase 2

and 26 more — sign in to see them all

32%
Phase 3

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%

Sino Biopharmaceutical: 26 of its 97 programs at phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. NTQ5082phase 3
  5. culmerciclibphase 3

and 21 more — sign in to see them all

27%
Approved, new studies

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Sino Biopharmaceutical: 3 of its 97 programs at approved, new studies

  1. catequentinib hydrochlorideapproved, new study
  2. Adalimumabapproved, new study
  3. TyboWe® Adalimumab Injectionapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
Sino Biopharmaceutical37 readouts · 10 phase 3

Sino Biopharmaceutical, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868phase 3 · Nov 0 · NCT06767813
  2. NTQ5082phase 3 · Nov 0 · NCT07177859
  3. TQB2252phase 1 · Nov 0 · NCT06649656
  4. TQH2722phase 3 · Nov 0 · NCT07398859

Sino Biopharmaceutical, Dec ’26: 14 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-HER2 Bispecific Antibody TQB2930phase 3 · Dec 0 · NCT06202261
  2. BET Inhibitor TQB3617phase 2 · Dec 0 · NCT06122831
  3. BTK Inhibitor TQB3702phase 2 · Dec 0 · NCT06859931
  4. catequentinib hydrochlorideapproved, new study · Dec 0 · NCT04344158
  5. culmerciclibphase 3 · Dec 0 · NCT05780567

and 9 more — sign in to see them all

Sino Biopharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3 · Jan 0 · NCT06561607
  2. vilzemetkibphase 3 · Jan 0 · NCT06860971

Sino Biopharmaceutical, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB6411phase 2 · Feb 0 · NCT07367516
  2. TQC3721phase 3 · Feb 0 · NCT07464587

Sino Biopharmaceutical, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anecatibin Fumarate Capsulesphase 1 · Mar 0 · NCT07538973
  2. TQB3473phase 3 · Mar 0 · NCT06900920
  3. TQC2938phase 2 · Mar 17 · NCT06789289

Sino Biopharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion

  1. NTQ6179phase 1 · Apr 0 · NCT07909837
  2. TQB3201phase 2 · Apr 0 · NCT07172126

Sino Biopharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. NTB003phase 2 · May 31 · NCT07462130
·

Sino Biopharmaceutical, Jul ’27: 2 programs whose next study reaches primary completion

  1. TQD3524phase 2 · Jul 0 · NCT07512596
  2. TQH3906phase 3 · Jul 0 · NCT06754891

Sino Biopharmaceutical, Aug ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB2916phase 2 · Aug 0 · NCT06962267
  2. TQB6426phase 1 · Aug 0 · NCT07730190
  3. trifluridine tipiracil drug combinationphase 3 · Aug 0 · NCT07483684
  4. LM-168phase 2 · Aug 1 · NCT06868199
  5. KYLO-0603phase 2 · Aug 15 · NCT07878091
·

Sino Biopharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3 · Oct 0 · NCT07179679
  2. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1 · Oct 30 · NCT04740424
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Sino Biopharmaceutical

New programs 3

  • NTQ6179phase 1 · first study · Oct 20 · Acromegaly
  • KYLO-0603phase 2 · first study · Sep 24 · Non-alcoholic Fatty Liver Disease
  • TQF6422phase 1 · first study · Aug 26 · Obesity

Reached a new phase 1

  • TQA3605phase 3 · Aug 28 · Hepatitis B, Chronic

Study stopped 0

None

Primary completion later 4

Where they overlap

Conditions where at least two of them have programs: 41 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionMerckSino Biopharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Sino Biopharmaceutical in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. vilzemetkibphase 3
  5. FHND-9041phase 3

and 5 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Sino Biopharmaceutical in Neoplasms: 2 programs

  1. LM-364phase 2
  2. LM-350phase 2

Their studies: Sino Biopharmaceutical’s studies of Neoplasms in search

Breast Neoplasmsboth · compare here

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Merck in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Pulmonary Disease, Chronic Obstructive in search

Sino Biopharmaceutical in Pulmonary Disease, Chronic Obstructive: 6 programs

  1. TQC2731phase 3
  2. TQC3721phase 3
  3. TQC2938phase 2
  4. TQC3927phase 2
  5. TQC3302phase 1

and 1 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Pulmonary Disease, Chronic Obstructive in search

Obesityboth · compare here

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Sino Biopharmaceutical in Obesity: 3 programs

  1. Semaglutidephase 3
  2. TQF3250phase 1
  3. TQF6422phase 1

Their studies: Sino Biopharmaceutical’s studies of Obesity in search

Diabetes Mellitus, Type 2both · compare here

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Sino Biopharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. Semaglutidephase 3

Their studies: Sino Biopharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Hematologic Neoplasmsboth · compare here

Merck in Hematologic Neoplasms: 1 program

  1. nemtabrutinibphase 3

Their studies: Merck’s studies of Hematologic Neoplasms in search

Sino Biopharmaceutical in Hematologic Neoplasms: 4 programs

  1. Bcl-2 Inhibitor TQB3909phase 3
  2. TQB2825phase 3
  3. TQB3473phase 3
  4. BTK Inhibitor TQB3702phase 2

Their studies: Sino Biopharmaceutical’s studies of Hematologic Neoplasms in search

Lung Neoplasmsboth · compare here

Merck in Lung Neoplasms: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. raludotatug deruxtecanphase 3
  3. Rescue Medicationsphase 2

Their studies: Merck’s studies of Lung Neoplasms in search

Sino Biopharmaceutical in Lung Neoplasms: 2 programs

  1. TQB6411phase 2
  2. Anecatibin Fumarate Capsulesphase 1

Their studies: Sino Biopharmaceutical’s studies of Lung Neoplasms in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Sino Biopharmaceutical in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. TQB2825phase 3
  2. gemcitabine-oxaliplatin regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Ovarian Neoplasmsboth · compare here

Sino Biopharmaceutical in Ovarian Neoplasms: 1 program

  1. vilzemetkibphase 3

Their studies: Sino Biopharmaceutical’s studies of Ovarian Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

Sino Biopharmaceutical in Small Cell Lung Carcinoma: 2 programs

  1. benmelstobartphase 3
  2. trifluridine tipiracil drug combinationphase 3

Their studies: Sino Biopharmaceutical’s studies of Small Cell Lung Carcinoma in search

Show all 41

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Merck 40 of 84 · Sino Biopharmaceutical 70 of 97 programs (21 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sino Biopharmaceutical: 19).